Due to their strong biological activity, heterocyclic compounds containing triazine scaffolds are now of interest to a large number of organic chemists. It has been discovered that the triazine ring possesses antiepileptic properties. The article's goal is to highlight these particular ring diversities of study using triazine moieties that include medications and patent numbers. A variety of antiepileptic medications are being developed and will soon be available in the market to treat aberrant neuronal excitability. Among the key objectives to deal with a number of disorders affecting the central nervous system, such as epilepsy, chronic pain, mental illnesses, and spasticity, are voltage-gated sodium channel blockers. By blocking intricate voltage and frequency-dependent ionic currents via sodium channels, they prevent seizures. Although the sodium channel has been arguably the most extensively researched target for seizure control or treatment over the last 10 years, no ground-breaking findings have been made as of yet. Despite the fact that several medications are licensed to treat epilepsy, they are linked to a range of acute and long-term adverse effects. To treat epileptic seizures, multiple teams of researchers have been working nonstop to develop improved therapeutic medications for this well-liked target. The evolution of authorized sodium channel blockers as anticonvulsant medications is briefly noted in the study. To reduce the toxicity, medicinal chemists have attempted to create several stronger anticonvulsant medications, which are covered below. Their potential mechanism and structure-activity relationship (SAR) is highlighted.